Sobi

Jun 14, 2020

Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program

Jun 25, 2019

Sobi Presents Study Data Supporting Increased Possibilities and Improved Clinical Outcomes for People With Haemophilia at ISTH

Mar 25, 2019

Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)

Feb 07, 2019

Sobi Presents Comprehensive Study Data on Extended Half-life Haemophilia Treatments at EAHAD

May 21, 2018

Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress

Apr 19, 2018

Invitation - Presentation of Sobi's Q1 2018 Results

Feb 28, 2018

Sobi Launches Enhanced Corporate Sustainability Initiative

Feb 07, 2018

The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's(TM) Extended Half-life Therapies